Akmon, a French start-up in Hong Kong, contacted PDD to request help with the development of a fashionable anti-pollution motorcycle face mask after experiencing frustration with competitive products. The two founders, both avid motorcycle fanatics, found current anti-pollution face masks on the market to be ineffective, uncomfortable, unfashionable and merely functional. In Asian most megacities are choked up with polluting vehicles and as a result the exposure of these dangerous particles to the public has reached alarming levels – a situation Akmon were determined to change.

The project revolved around two main objectives: how to increase the efficiency of the filter components and how to transform a utilitarian product into a fashion item for men, woman and children. PDD and Akmon went to enormous efforts to fine-tune and optimise the ergonomic aspects of the different mask sizes and the exchangeability of the inner filter (which opened an entire market of after sales products for Akmon).

Fashionable soft goods are known for their complexity but through close collaboration with Akmon’s fashion designer as well as the fabric prototyping resources, the PDD team was able to find the best solution between Caucasian and Asian ergonomics. By offering a number of fabric and colour choices the mask appeals to both motorcycle enthusiasts as well as fashion conscious individuals. Traditional anti-pollution face masks tend to look medical and are often in efficient, in contrast Akmon’s face mask breaks new ground into the fashion world.

Buy the Akmon anti-pollution face mask by visiting akmonconcept.com

If you would like to learn more about this project or PDD services, contact PDD on:
e. [email protected]
t. +44 (0)20 8735 1111

 


News & Insights

27/07/2017

PDD completes its transition to the 2016 version of ISO13485 for Medical Devices.

PDD has completed its planned transition to the latest version of this rigorous international quality assurance standard for medical devices, building on the success of earlier transitions and successful audits to the FDA 21CFR Part 820 in 2015.